These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36401810)

  • 1. Performance of the Pooled Cohort Equations in non-alcoholic fatty liver disease: The Multi-Ethnic Study of Atherosclerosis.
    Henson JB; Budoff MJ; Muir AJ
    Liver Int; 2023 Mar; 43(3):599-607. PubMed ID: 36401810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index.
    Khera R; Pandey A; Ayers CR; Carnethon MR; Greenland P; Ndumele CE; Nambi V; Seliger SL; Chaves PHM; Safford MM; Cushman M; Xanthakis V; Vasan RS; Mentz RJ; Correa A; Lloyd-Jones DM; Berry JD; de Lemos JA; Neeland IJ
    JAMA Netw Open; 2020 Oct; 3(10):e2023242. PubMed ID: 33119108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of coronary artery calcium score for the prediction of atherosclerotic cardiovascular disease in participants with suspected nonalcoholic hepatic steatosis: Results from the multi-ethnic study of atherosclerosis.
    Ichikawa K; Hansen S; Manubolu VS; Pourafkari L; Fazlalizadeh H; Aldana-Bitar J; VanWagner LB; Krishnan S; Budoff MJ
    Am Heart J; 2023 Nov; 265():104-113. PubMed ID: 37517431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
    Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
    Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.
    Fracanzani AL; Tiraboschi S; Pisano G; Consonni D; Baragetti A; Bertelli C; Norata D; Valenti L; Grigore L; Porzio M; Catapano A; Fargion S
    Atherosclerosis; 2016 Mar; 246():208-13. PubMed ID: 26803429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study.
    Lee SB; Park GM; Lee JY; Lee BU; Park JH; Kim BG; Jung SW; Jeong ID; Bang SJ; Shin JW; Park NH; Yang DH; Kang JW; Lim TH; Kim HK; Choe J; Lee HC
    J Hepatol; 2018 May; 68(5):1018-1024. PubMed ID: 29274406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study.
    Pereira ENGDS; Paula DP; de Araujo BP; da Fonseca MJM; Diniz MFHS; Daliry A; Griep RH
    World J Gastroenterol; 2021 Aug; 27(29):4913-4928. PubMed ID: 34447235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
    Lake JE; Taron J; Ribaudo HJ; Leon-Cruz J; Utay NS; Swaminathan S; Fitch KV; Kileel EM; Paradis K; Fulda ES; Ho KS; Luetkemeyer AF; Johnston CD; Zanni MV; Douglas PS; Grinspoon SK; Lu MT; Fichtenbaum CJ;
    AIDS; 2023 Nov; 37(14):2149-2159. PubMed ID: 37503623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease.
    Wu T; Ye J; Gong X; Li X; Shao C; Li F; Lin Y; Ma Q; Mai W; Wang W; Feng ST; Zhong B
    Dig Liver Dis; 2021 Dec; 53(12):1610-1619. PubMed ID: 33744170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.
    Pennisi G; Di Marco V; Buscemi C; Mazzola G; Randazzo C; Spatola F; Craxì A; Buscemi S; Petta S
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2389-2396. PubMed ID: 33871081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease.
    Guleria A; Duseja A; Kalra N; Das A; Dhiman R; Chawla Y; Bhansali A
    Trop Gastroenterol; 2013; 34(2):74-82. PubMed ID: 24377153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Risk Prediction Models for Atherosclerotic Cardiovascular Disease in a Prospective Korean Community-Based Cohort.
    Bae JH; Moon MK; Oh S; Koo BK; Cho NH; Lee MK
    Diabetes Metab J; 2020 Jun; 44(3):458-469. PubMed ID: 31950769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.
    Han AL
    BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis.
    Simon TG; Trejo MEP; Zeb I; Frazier-Wood AC; McClelland RL; Chung RT; Budoff MJ
    Metabolism; 2017 Oct; 75():1-5. PubMed ID: 28964324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining European and U.S. risk prediction models with polygenic risk scores to refine cardiovascular prevention: the CoLaus|PsyCoLaus Study.
    de La Harpe R; Thorball CW; Redin C; Fournier S; Müller O; Strambo D; Michel P; Vollenweider P; Marques-Vidal P; Fellay J; Vaucher J
    Eur J Prev Cardiol; 2023 May; 30(7):561-571. PubMed ID: 36652418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.
    Tang ASP; Chan KE; Quek J; Xiao J; Tay P; Teng M; Lee KS; Lin SY; Myint MZ; Tan B; Sharma VK; Tan DJH; Lim WH; Kaewdech A; Huang D; Chew NW; Siddiqui MS; Sanyal AJ; Muthiah M; Ng CH
    Clin Mol Hepatol; 2022 Jul; 28(3):483-496. PubMed ID: 35232007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults.
    Nanna MG; Peterson ED; Wojdyla D; Navar AM
    J Gen Intern Med; 2020 Jun; 35(6):1701-1708. PubMed ID: 31667745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes.
    Guo K; Zhang L; Lu J; Yu H; Wu M; Bao Y; Chen H; Jia W
    J Diabetes Complications; 2017 Jan; 31(1):80-85. PubMed ID: 27742552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease.
    Sukahri S; Mohamed Shah FZ; Ismail AI; Koshy M; Johari B; Mohd Razali M; Abdul Rahman TH; Isa MR; Abdul Ghani R
    PLoS One; 2021; 16(6):e0253298. PubMed ID: 34191823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.